SCHEMBL6750837

SCHEMBL6750837

CC(C1CCCCN1)N1C(=O)CN(Cc2ccc(OCc3ccccc3)cc2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.45
ENPP2 Q13822 1/20 0.43
MMP13 P45452 1/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
NPC1 O15118 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
LTA4H P09960 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
KDM4C Q9H3R0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5669924 0.91 POLB (0.43) ENPP2MEN1KMT2AALDH1A1ALOX15
SCHEMBL5672396 0.83 HCRTR1 (0.43) ENPP2MMP13MEN1KMT2AALDH1A1
SCHEMBL28757290 0.83 LTA4H (0.41) GRM2ENPP2MMP13TP53MEN1
SCHEMBL6750846 0.80 SLC6A3 (0.41) ENPP2
SCHEMBL6750833 0.77 NPY1R (0.47) GRM2MMP13TP53SMN1; SMN2HTR2C
SCHEMBL3183974 0.70 HTR2C (0.49) HTR2CHTR2BLTA4H
SCHEMBL5669916 0.68 KCNH2 (0.41) MEN1KMT2AALOX15L3MBTL1LTA4H
SCHEMBL5398635 0.67 KCNA5 (0.40) SMN1; SMN2ALDH1A1ALOX15L3MBTL1LMNA
SCHEMBL3177594 0.67 GRM2 (0.60) GRM2MMP13TP53SMN1; SMN2NPC1
SCHEMBL5884184 0.67 PDE6D (0.46) TP53KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1671387-A Aryl substituted hydantoin compounds and their use as sodium channel blockers EURO CELTIQUE SA (LU) 2005-09-21 CN claimed
US-20040097569-A1 Aryl substituted hydantoin compounds and their use as sodium channel blockers EURO-CELTIQUE S.A. 2004-05-20 US claimed
CN-1671387-A Aryl substituted hydantoin compounds and their use as sodium channel blockers EURO CELTIQUE SA (LU) 2005-09-21 CN disclosed
US-20040097569-A1 Aryl substituted hydantoin compounds and their use as sodium channel blockers EURO-CELTIQUE S.A. 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097569-A1 Aryl substituted hydantoin compounds and their use as sodium channel blockers SCN1A, CACNA1S, SCN1B GRM2 816/4885ENPP2 2941/4885MMP13 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.